Joined October 2013
- Tweets 2,570
- Following 205
- Followers 1,105
- Likes 178
221 Photos and videos
The Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation in Alzheimer’s disease, sponsored by IGC Pharma, has reached its previously disclosed 146-patient randomization target
Read More: finance.yahoo.com/sectors/he…
#AlzheimersResearch
1
1
90
Ascendiant Capital Markets has issued an updated equity research report on IGC Pharma, raising its price target to $5.50 per share.
Read more: finance.yahoo.com/sectors/he…
#IGCPharma #NYSEAmerican
1
2
60
IGC Pharma, Inc. NYSE American: IGC retweeted
Exclusive Investor Evening | Hudson Yards, NYC
Meet Ram Mukunda, Founder & CEO of @IGCIR (NYSE American: IGC), at an exclusive invitation-only event by @NewToTheStreet. @vincemedia1
📅 June 11, 2026
⏰ 5:30 PM – 7:30 PM
Connect with accredited investors, industry leaders, and executives during an evening of networking, company insights, and private dining.
Space is limited. Request your invitation today.
RSVP TODAY!
john@newtothestreet.com
#IGCPharma #Biotech #Alzheimer #Innovation #NewToTheStreet
3
1
1,124
The Icahn School of Medicine at Mount Sinai (@IcahnMountSinai) has been added as a clinical site in IGC Pharma’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease.
Read more: finance.yahoo.com/sectors/he…
#AlzheimersResearch
1
73
Agitation remains one of the most prevalent and challenging symptoms in Alzheimer’s disease
Understanding its behavioral patterns is essential for advancing research and supporting the development of more targeted therapeutic strategies
#AlzheimersResearch #IGCPharma
1
40
On #ClinicalTrialsDay, we recognize the role of structured, patient-centered research in advancing medicine
Scientific rigor, regulatory responsibility, and participant trust remain at the core of progress in Alzheimer’s research
#AlzheimersResearch
3
72
New Tau-PET biomarker research by IGC Pharma was presented at the 2026 Global Tau Conference
The poster evaluated whether Shannon entropy may quantify tau pathology heterogeneity
Read more: finance.yahoo.com/sectors/he…
#AlzheimersDisease #AIinHealthcare #IGCPharma
2
64
Research suggests important differences in how Alzheimer’s disease affects men and women, from prevalence to progression
Here’s what current evidence shows ⬇️
#AlzheimersResearch #Neuroscience
1
2
65
Caregiver dynamics add another dimension
Women are more likely to both develop Alzheimer’s and serve as caregivers, shaping how the disease is experienced socially and clinically ⬇️
1
43
Understanding demographic differences is essential for advancing research, improving clinical trial design, and refining therapeutic development
(Source: Alzheimer’s Association; National Institute on Aging)
#AlzheimersDisease #IGCPharma
35
Music is being studied as a neurologically grounded phenomenon in Alzheimer’s disease
Research explores preserved musical memory networks and how music-based interventions may influence mood and behavior
Read more: igcpharma.com/musical-memori…
#AlzheimersResearch #Neuroscience
2
3
205
Times Square marks another step in our journey
A reminder of the global scale of Alzheimer’s disease and the responsibility that comes with advancing research in this field
Scientific rigor and disciplined execution remain at the core of our work
#AlzheimersResearch #Biotech #IGCPharma
1
5
274
Caregiver burden is a critical dimension of Alzheimer’s disease
Recognizing its scope helps inform better clinical priorities, including addressing symptoms like agitation that impact daily life
Learn more about CALMA: igcpharma.com/calma/
#AlzheimersCare #AlzheimersDisease
1
3
180
As part of caregiver engagement efforts, IGC Pharma joined the caregiver-focused podcast Autumn Is Here to discuss agitation as a clinically significant symptom of Alzheimer’s disease
Read more: finance.yahoo.com/sectors/he…
#AlzheimersDisease #CaregiverSupport
3
67
Kerwin Medical Center in Dallas has been added as a clinical site in the ongoing Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease. Enrollment is now ~80%.
Read more: finance.yahoo.com/sectors/he…
#AlzheimersResearch
2
78
IGC Pharma has received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá.
Read More: finance.yahoo.com/sectors/he…
#AlzheimersDisease #ClinicalResearch
1
2
106
#AlzheimersResearch depends on clinical, imaging, and biomarker data collected across institution
But these datasets often use different formats, encodings, and standards
They don’t automatically “speak the same language” ⬇️
1
1
100
Harmonization isn’t just a technical task
It’s research infrastructure
Scalable, interoperable data systems are essential to accelerating Alzheimer’s discovery ⬇️
1
74
Initiatives like aha™ (Agentic Harmonization Assistant) are designed to help address this integration challenge
Advancing science requires integration at scale
Learn more: igcpharma.com/aha-agentic-ha…
#AIinHealthcare #DataScience #ResearchInfrastructure
78